reason report
adopt tougher stick unchang
pt
bottom line morn share trade meaning
reaction consecut sale missaft deliv meaning
beat prior quarter lower sale
growth guidanc shaken confid
warrant view believ compani enter anoth
phase impella adopt curv one increment sale
get tougher need convert low-volum users/non-
believ follow taglin train data time question
us becom much time redirect focu toward
commun hospit better train around access closur
educ non-believ total clinic data actual
take believ could take longer quarter two
sustain growth reacceler also believ happen
believ total impella data support util safeti
cost-effect high risk pci cardiogen shock
procedur think even one
believ compani patient estim still
balloon pump use annuallya devic
random control clinic trial support fda approv fail
random control clinic trial shock ii statist
significantli inferior impella random control trial look
major advers event day us argument use impella
patient current get balloon pump strong
patient get balloon pump today would almost tripl
current impella volum valuat perspect
smid-cap med-tech group trade sale overal
higher-growth group trade view someth
ev/sal rang flooror use new
estim even sale growth compani abmd-
like margin profil deserv trade premium overal group
view think potenti upsid
now-low multiplewhich put us share could drift
bit rebound remain op ultim
think stabil sale growth reacceler
adopt ramp next quarter just-announc
reiter op pt price target vs prior appli
ev/sal multipl now-low estim
assum current multipl hold steadi continu
believ top-tier sale growth profil profit warrant
in-lin multipl vs compar higher-growth smid-cap med-tech
groupconsist
wmgiaverag
medic suppli devic
ev/sal multipl
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu dilut gaap ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
estim adjust newli issu guidanc revenue/
ep decreas vs prior line
midpoint compani newli issu revenu oper
margin guidanc rang revenue/ep move
rate share outperform price target believ abiom
manufactur impella famili percutan ventricular assist devic pvad well-
posit deliv sustain strong double-digit sale growth near-to-midterm
time-frame project sale compound-annual-growth-rate
compani drive increas penetr prophylact high-risk percutan
coronari intervent pci cardiogen shock patient popul estim nearli
patient treat abiom impella impella cp
pci perform annual base medacorp physician
convers anywher pci could consid high-risk
would benefit impella anoth pci cardiogen shock patient
compani benefit new product higher flow impella cp receiv pma approv
 april indic shock new geographi notabl
japan receiv approv octob launch impella
addit receiv fda approv impella rp right heart failur
compani continu add new center
center total ad center per quarter
us biggest barrier impella adopt awar impella
pma-approv protect pci impella devic includ higher flow impella
cp approv cardiogen shock aggress market train
hospit heart team util broad clinic dataset train capabl impella
six clinic guidelin drive awar help guid clinic
practic eas patient select
even adopt inflect upon protect pci pma approv late believ
impella adopt pois ramp given
highli under-penetrated market opportun within protect pci cardiogen shock
impella today penetr
concert effort among physician rais awar around treat grow
number complex patient pci procedur volum patient grow
mid-single-digit rang base estim
pma approv protect pci cardiogen shock allow
aggress market impella use broad clinic dataset support safeti efficaci
cost-effect well train clinician nurs
indic geograph expans on-going launch impella rp
patient opportun on-going launch japan current
patient balloon pump patient extracorpor membran
oxygen ecmo repres low-hang fruit impella view
oper margin expans stori believ abiom drive on-going posit oper
leverag primarili within sg ultim push oper margin
next month believ share
move higher current level compani continu deliv consist quarterli sale
beat push oper margin higher
price target vs prior appli ev/sal multipl now-low
estim assum current multipl hold steadi continu
believ top-tier sale growth profil profit warrant in-lin multipl vs
compar higher-growth smid-cap med-tech group -- consist
nr nr nr -- averag
risk rate valuat includ failur drive increas util rate
and/or continu add new account steadi rate failur execut pipelin
launch new geographi potenti reimburs declin potenti competit
pvad product secur approv gain meaning market share potenti
dollar million except per share data
total good sold
research develop expens
consensu incom statement item includ contributor factset
revenu
servic revenu
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
total good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
servic revenu
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
total good sold
research develop
cog sale
sg sale
 sale
oper expens sale
compani report svb leerink estim
abiom sale y/i
share-bas
pivot compar today standard care immedi reperfus without
ecp expand cardiac power true cathet target three
liter flow ideal pump high-risk pci physician want
anyth larger way pump short area
inflow valv thin soft membran abras
valv ecp deliv design clinic durat
hour fr pump expand fr
impella btr expect later outer year estim flow l/min
cathet fr pump shorter design durat month year
also wearabl driver allow patient get discharg
hospit impella btr minim invas approach axillari arteri
bridg
 jan close final
detail trial fda expect
start second half
still pre-clin test aug
-a februari first-in-man ecp still
expect
 jan first-in-man ecp expect
impella next gener pump smaller profil design
implant axillari arteri wean algorithm implant
axillari arteri allow greater flexibl patient walk around hospit
may improv outcom
jan control eu launch underway
patient alreadi germani
jan first-in-man expect
